PLoS ONE (Jan 2023)

Diisocyanates influence models of atopic dermatitis through direct activation of TRPA1.

  • Manoj Yadav,
  • Prem Prashant Chaudhary,
  • Brandon N D'Souza,
  • Grace Ratley,
  • Jacquelyn Spathies,
  • Sundar Ganesan,
  • Jordan Zeldin,
  • Ian A Myles

DOI
https://doi.org/10.1371/journal.pone.0282569
Journal volume & issue
Vol. 18, no. 3
p. e0282569

Abstract

Read online

We recently used EPA databases to identify that isocyanates, most notably toluene diisocyanate (TDI), were the pollutant class with the strongest spatiotemporal and epidemiologic association with atopic dermatitis (AD). Our findings demonstrated that isocyanates like TDI disrupted lipid homeostasis and modeled benefit in commensal bacteria like Roseomonas mucosa through disrupting nitrogen fixation. However, TDI has also been established to activate transient receptor potential ankyrin 1 (TRPA1) in mice and thus could directly contribute to AD through induction of itch, rash, and psychological stress. Using cell culture and mouse models, we now demonstrate that TDI induced skin inflammation in mice as well as calcium influx in human neurons; each of these findings were dependent on TRPA1. Furthermore, TRPA1 blockade synergized with R. mucosa treatment in mice to improve TDI-independent models of AD. Finally, we show that the cellular effects of TRPA1 are related to shifting the balance of the tyrosine metabolites epinephrine and dopamine. This work provides added insight into the potential role, and therapeutic potential, or TRPA1 in the pathogenesis of AD.